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Abstract
High serum phosphorus levels have been associated with mortality and cardiovascular events in patients with chronic
kidney disease and in the general population. In addition, high phosphorus levels have been shown to induce vascular
calcification and endothelial dysfunction in vitro. The aim of this study was to evaluate the relation of phosphorus and
coronary calcification and atherosclerosis in the setting of normal renal function. This was a cross-sectional study involving
290 patients with suspected coronary artery disease and undergoing elective coronary angiography, with a creatinine
clearance .60 ml/min/1.73 m2. Coronary artery obstruction was assessed by the Friesinger score and coronary artery
calcification by multislice computed tomography. Serum phosphorus was higher in patients with an Agatston score .10
than in those with an Agatston score #10 (3.6360.55 versus 3.4960.52 mg/dl; p = 0.02). In the patients with Friesinger
scores .4, serum phosphorus was higher (3.660.5 versus 3.560.6 mg/dl, p = 0.04) and median intact fibroblast growth
factor 23 was lower (40.3 pg/ml versus 45.7 pg/ml, p = 0.01). Each 0.1-mg/dl higher serum phosphate was associated with a
7.4% higher odds of having a Friesinger score .4 (p = 0.03) and a 6.1% greater risk of having an Agatston score .10
(p = 0.01). Fibroblast growth factor 23 was a negative predictor of Friesinger score (p = 0.002). In conclusion, phosphorus is
positively associated with coronary artery calcification and obstruction in patients with suspected coronary artery disease
and preserved renal function.
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Introduction
High serum phosphorus has long been associated with increased
mortality and cardiovascular events in patients with chronic
kidney disease (CKD) [1,2], and recent studies have extended
those observations to the general population [3,4]. In patients with
preserved renal function, high-normal serum phosphorus has also
been linked to the severity of coronary artery disease (CAD), as
seen on coronary angiography [5,6], as well as to increased carotid
intima-media thickness [7] and ventricular hypertrophy [8].
There is increasing evidence that other mineral metabolism
regulators are involved in the pathogenesis of cardiovascular
disease. Phosphorus homeostasis is maintained by various
hormones, mainly parathyroid hormone (PTH), calcitriol, and
fibroblast growth factor 23 (FGF23). Excess PTH, as is seen in
primary and secondary hyperparathyroidism [9,10], is associated
with increased mortality, and high PTH levels have been related to
fatal events in the general population [11]. Vitamin D deficiency
also has an impact on the incidence of cardiovascular events [12].
The phosphaturic hormone FGF23 decreases the production of
1,25-hydroxyvitamin D and PTH [13]. High phosphorus intake is
the main stimulus for FGF23 synthesis by osteocytes [14]. In CKD
patients, high levels of FGF23 have been associated with mortality
[15], myocardial hypertrophy [16], and CAD [17]. Other
populational studies have also shown that FGF23 is related to
atherosclerosis [18], mortality, and cardiovascular events [19].
Those studies, however, included patients with renal dysfunction.
Therefore, in this study, we looked for associations between
mineral metabolism and CAD in a cross-sectional study of patients
with preserved kidney function and suspected CAD. We evaluated
several markers of mineral homeostasis, as well as the presence of
CAC and coronary artery obstruction, using the Agatston score
(AS) to quantify CAC [20] and the Friesinger score (FS) to
quantify coronary obstruction [21].
Methods
Participants
This was a cross-sectional study involving 290 clinically stable
patients with suspected CAD submitted to elective coronary
angiography, as ordered by their attending physicians, between
June 2008 and December 2009 at the Heart Institute of Hospital
das Clı´nicas, University of Sa˜o Paulo School of Medicine. The
inclusion criteria were an age higher than 18 years and an
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estimated Glomerular Filtration rate (eGFR).60 ml/min/
1.73 m2, as calculated by the Modification of Diet in Renal
Disease formula [22]. Exclusion criteria were the presence of any
hepatic, renal, autoimmune diseases, malignancy, myocardial
revascularization, coronary angioplasty, and current use of
bisphosphonates, calcium supplements, vitamin D supplements,
steroids, or anticonvulsants. Data on medical history and
anthropometry were obtained prior to coronary angiography,
and blood sampling was drawn at the day of cardiac computed
tomography.
Ethics Statement
The study was reviewed and approved by the local institutional
ethics board, Comiteˆ de E´tica para a Ana´lise de Projetos de Pesquisa do
Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o
Paulo (process number 0755/07). All participating patients gave
written informed consent.
Biochemical Analysis
Whole blood was collected after a 12 h fast, and creatinine,
urea, total calcium, ionized calcium, phosphorus, intact PTH
(immunochemiluminometric assay, reference range, 16–87 pg/ml;
DPC, Los Angeles, California), total alkaline phosphatase,
25(OH)D (radioimmunoassay kit, reference range .30.0 ng/ml;
DiaSorin, Stillwater, Minnesota), intact FGF23 (ELISA kit,
reference range 27.8–50.0 pg/ml; Kainos, Tokyo, Japan), C-
reactive protein, total cholesterol, high- and low-density lipopro-
tein cholesterol, triglycerides, apolipoprotein B, glucose, and C-
peptide were determined.
Cardiac Computed Tomography
Multislice computed tomography was performed in a scanner
with 64 detector rows (Aquilion 64; Toshiba, Otawara, Japan). To
determine the initial and final level of the scan, all patients were
monitored electrocardiographically for synchronization with
image acquisition. A chest X-ray was acquired in apnea. Images
were obtained using a protocol in which 64 slices (each 3 mm
thick) were obtained, with image acquisition triggered at 80% of
the RR interval. Calcification was quantified by calculating the AS
on a workstation (Vitrea 2, version 3.5; Vital Images Inc,
Plymouth, Minnesota). Coronary calcifications were defined as
four or more contiguous pixels with a density of $130 Hounsfield
units. The total AS was calculated as the sum of the individual
scores for the four major epicardial coronary arteries [20].
Coronary Angiography
Patients were submitted to coronary angiography in the
Hemodynamics Laboratory of the Heart Institute, and standard
procedures were used. To evaluate the burden of atherosclerotic
disease, Friesinger score was calculated. In order to calculate the
FS, left anterior descendent, circumflex, and right coronary
arteries each receive 0–5 points depending on the degree of
coronary obstruction, and the total FS being the sum of those
three values) [21].
Statistical Analysis
Continuous parametric variables are expressed as mean 6
standard deviation, and nonparametric variables are expressed as
median and interquartile range. For the univariate analysis, we
used the Mann-Whitney and the chi-square tests. Kruskal-Wallis
test was applied for the analyses of tertiles of phosphorus.
We then constructed several univariate and multivariate linear
regression models using phosphorus and log FGF23 as the
dependent variables. For the logistic regression analyses, our
patients were divided according to CAC (no-CAC group, AS#10;
and CAC group, AS.10) [23] and Friesinger values (higher and
upper the median value).
All tests were two-tailed, and the level of significance was set at
5%. All statistical analyses were performed with the Statistical
Table 1. Basic characteristics of the study populationa.
Characteristic Value
Male, % 57.5
Age (years), mean 6 SD 58.169.3
Race, %
White 64.8
Non-white 35.2
Clinical data, %
Hypertension 81.0
Diabetes 35.5
Dyslipidemia 45.2
Heart failure 19.7
Body mass index .25 kg/m2 28.6
Current smoking 32.1
Statin use 51.7
BMI (kg/m2), mean 6 SD 28.064.9
SBP (mmHg), mean 6 SD 131.2618.8
DBP (mmHg), mean 6 SD 82.3611.9
Agatston score, median (IQR) 46 (0–297)
Friesinger score, median (IQR) 4 (4–9)
Biochemical data
Alkaline phosphatase (U/L), mean 6 SD 71624
Total calcium (mg/dl), mean 6 SD 9.560.5
Ionized calcium (mg/dl), median (IQR) 5.1 (5.0–5.3)
Phosphorus (mg/dl), mean 6 SD 3.5760.54
25(OH)D (ng/ml), mean 6 SD 23.968.5
PTH (pg/ml), median (IQR) 57.5 (41–78.2)
FGF23 (pg/ml), median (IQR) 43.8 (27.0–68.8)
Creatinine (mg/dl), mean 6 SD 0.8960.17
Urea (mg/dl), median (IQR) 36.5 (30–44.3)
Glucose (mg/dl), median (IQR) 105 (94–121)
Apolipoprotein B (mg/dl), mean 6 SD 86625
Total cholesterol (mg/dl), mean 6 SD 172642
HDL cholesterol (mg/dl), median (IQR) 43 (36–52)
LDL cholesterol (mg/dl), mean 6 SD 97635
VLDL cholesterol (mg/dl), median (IQR) 26 (19–37)
Triglycerides (mg/dl), median (IQR) 131 (97–190)
C-reactive protein (mg/L), median (IQR) 2.8 (1.2–5.3)
C-peptide (ng/ml), median (IQR) 2.6 (1.8–3.7)
eGFR (ml/min/1.73 m2), median (IQR) 92.0 (79.1–109.0)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; 25(OH)D, 25-hydroxyvitamin D; HDL, High-density lipoprotein; LDL,
Low-density lipoprotein; VLDL, very low-density lipoprotein; eGFR, estimated
GFR.
aNormally distributed variables are expressed as mean 6 SD and non-normally
distributed variables are expressed as median (IQR).
doi:10.1371/journal.pone.0036883.t001
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Package for the Social Sciences, version 13.0 (SPSS Inc., Chicago,
Illinois).
Results
Baseline Clinical and Laboratory Characteristics
Table 1 shows the baseline characteristics of the study
population, with a significant proportion of diabetics and
hypertensive (35.5 and 81.0%, respectively). The median AS was
46.5. We found the prevalence of hypovitaminosis D (,30 ng/ml)
to be 75.9% in the study population.
Calcification
Of the 290 patients evaluated, 92 (31.7%) had an AS of 0.
When patients were classified according to AS (Table 2), those
with an AS.10 (CAC group) were older and showed a higher
frequency of male gender, hypertension, and diabetes. In the CAC
group, serum phosphorus was significantly higher and PTH
showed a near-significant association with CAC (p= 0.06). There
were no differences between the two groups regarding FGF23,
ionized calcium, alkaline phosphatase, or 25(OH)D. In addition,
the CAC group presented lower levels of apolipoprotein B, total
cholesterol, and low-density lipoprotein cholesterol, and a higher
frequency of statins use.
When the population was divided into tertiles of serum
phosphorus, we observed that median AS increased progressively
(p=0.01), as shown in Figure 1.
Table 3 shows the logistic regression related to the risk of having
an AS.10. In the univariate analysis, we found that each 0.1-mg/
dl rise in serum phosphorus was associated with a 6.1% higher
odds of having an AS.10. Phosphorus remained a significant risk
factor for CAC even after adjustment for multiple variables such as
age, gender, diabetes, hypertension, FGF23 level, and PTH
concentration. As expected, traditional risk factors such as age,
gender, hypertension, and diabetes were also strong predictors of
an AS.10. In the univariate analysis, log PTH was negatively
associated with the risk of CAC, although this association
disappeared in the multivariate analysis (Table 3). Other mineral
metabolism markers, including FGF23, calcium, and alkaline
phosphatase, were not predictors of CAC in our sample.
Table 2. Characteristics of the patients evaluated, by Agatston scorea.
Characteristic No-CAC Group CAC Group p
AS#10 AS.10
(n =121) (n=169)
Age (years), mean 6 SD 54.768.8 60.468.9 ,0.001
Male gender, % 49.3 63.3 0.02
Hypertension, % 72.7 86.9 0.004
Diabetes, % 24.8 43.2 0.001
Current smoking, % 29.7 33.7 0.5
Statin use, % 42.9 57.9 0.01
Alkaline phosphatase (U/L), mean 6 SD 76622 78625 0.89
Total calcium (mg/dl), mean 6 SD 9.460.5 9.560.5 0.2
Ionized calcium (mg/dl), median (IQR) 5.1 (4.9–5.3) 5.1 (5.0–5.3) 0.1
Phosphorus (mg/dl), mean 6 SD 3.560.5 3.660.5 0.02
25(OH)D (ng/ml), mean 6 SD 23.668.4 24.268.7 0.43
PTH (pg/ml), median (IQR) 61 (43.5–85) 53 (38–76) 0.06
FGF23 (pg/ml), median (IQR) 45.7 (28.6–76.8) 42.1 (26.1–65.3) 0.21
Creatinine (mg/dl), mean 6 SD 0.960.2 0.960.2 0.9
Urea (mg/dl), median (IQR) 37 (29–45) 36 (30–44) 0.8
Glucose (mg/dl), median (IQR) 101 (91.5–119) 106 (96–129) 0.03
Apolipoprotein B (mg/dl), mean 6 SD 92628 82622 0.006
Total cholesterol (mg/dl), mean 6 SD 182645 164637 ,0.001
HDL cholesterol (mg/dl), median (IQR) 44 (35–54) 43 (36–52) 0.8
LDL cholesterol (mg/dl), mean 6 SD 106637 91631 ,0.001
VLDL cholesterol (mg/dl), median (IQR) 26 (10–405) 26 (20–36) 0.6
Triglycerides (mg/dl), median (IQR) 132 (94–202) 129 (99–181) 0.5
C-reactive protein (mg/L), median (IQR) 2.7 (1.3–4.9) 2.9 (1.2–5.7) 0.6
C-peptide (ng/ml), median (IQR) 2.6 (1.8–3.5) 2.6 (1.8–3.7) 0.5
eGFR (ml/min/1.73 m2), median (IQR) 90.5 (77.6–106.6) 93.1 (79.6–110.7) 0.5
Friesinger score, median (IQR) 0 (0–3) 8 (4–11) ,0.001
25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; HDL, High-density lipoprotein; LDL, Low-density lipoprotein, VLDL, very low-density lipoprotein, eGFR,
estimated GFR.
aNormally distributed variables are expressed as mean 6 SD and non-normally distributed variables are expressed as median (IQR).
doi:10.1371/journal.pone.0036883.t002
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Coronary Angiography
Table 4 shows the characteristics of the patients by FS. Mean
age was higher in the .4 FS group than in the #4 FS group, as
were the proportions of males, hypertensive patients, diabetic
patients, and patients using statins. Serum phosphorus was
significantly higher and FGF23 was lower in the group with
higher Friesinger score.
Table 5 shows the logistic regression models on Friesinger score.
Age, male gender, hypertension, diabetes and AS were all
significantly associated with FS, whereas, in the univariate
analysis, serum phosphorus was not. However, after adjustment
for gender and other variables (gender, race, age, hypertension,
diabetes, logPTH and logFGF23), serum phosphorus showed a
positive association, with 0.1-mg/dl increase in phosphorus being
associated with a 7.4% higher odds of having higher Friesinger
score. Conversely, FGF23 was a negative predictor of FS, both in
the univariate and multivariate models.
Biochemical Variables
We attempted to identify the determinants of serum phosphorus
and FGF23. Serum phosphorus was higher in females than in
males (3.6560.49 mg/dl versus 3.5260.57 mg/dl; p=0.04), a fact
in accordance to the effect of gender in the logistic regression
models. Interestingly, serum phosphorus did not correlate
significantly with other mineral metabolism markers, such as
FGF23, PTH, 25(OH)D, and calcium. In the stepwise linear
regression model including phosphorus as the dependent variable
and age, sex, race, smoking status, hypertension, diabetes, BMI,
25(OH)D, logPTH, logFGF23, urea and creatinine clearance as
possible determinants, only urea, creatinine clearance, and gender
remained as determinants of serum phosphorus, collectively
explaining 6% of its variation (R2 = 0.06).
We found that FGF23 correlated positively with total calcium
(R= 0.197; p,0.001) but not with serum phosphorus, logPTH, or
25(OH)D. We also performed a stepwise linear regression model
on the FGF23 adjusted for age, gender, race, smoking, hyperten-
sion, diabetes, body mass index, 25(OH)D, total calcium,
phosphorus, log PTH, urea, and creatinine clearance. Again,
only total calcium remained significantly associated with serum
intact FGF23, explaining 3% of the variation in the latter
(R2 = 0.03).
Discussion
To our knowledge, this is the first study to evaluate the
associations between CAD and all of the major mineral
metabolism markers, including phosphorus, FGF23, 25(OH)D,
PTH, and calcium. It was also the first study to evaluate such
associations using CAC and coronary artery obstruction as
outcome measures in patients with preserved kidney function.
Even after adjusting for traditional cardiovascular risk factors, we
found that serum phosphorus was a strong predictor of CAC and
coronary artery obstruction, whereas FGF23 correlated negatively
with such obstruction.
Figure 1. Agatston scores by serum phosphorus tertiles. Results
are expressed as medians. Agatston scores were progressively higher
across phosphorus tertiles (P = 0.01).
doi:10.1371/journal.pone.0036883.g001
Table 3. Univariate and multivariate logistic regression
analysis of the risk of having an Agatston score .10.
Variable OR 95% CI p
Univariate analysis
Age 1.07 1.04–1.10 ,0.001
Male gender 1.75 1.09–2.82 0.02
White 1.32 0.81–2.14 0.27
Diabetes 2.31 1.38–3.85 0.001
Hypertension 2.51 1.37–4.57 0.003
Smoking 0.83 0.51–1.37 0.47
Phosphorus 1.61 1.03–2.51 0.03
Total calcium 1.42 0.86–2.33 0.17
Alkaline phosphatase 1.00 0.99–1.01 0.68
Glucose 1.00 0.99–1.01 0.19
LDL cholesterol 0.99 0.98–0.99 ,0.001
eGFR (ml/min/1.73 m2) 1.00 0.99–1.01 0.74
Log PTH 0.34 0.11–0.99 0.05
Log FGF23 0.56 0.26–1.22 0.14
Multivariate models
Model 1
Phosphorus 1.56 0.99–2.14 0.05
Log FGF23 0.58 0.26–1.27 0.17
Log PTH 0.39 0.13–1.17 0.09
Model 2
Phosphorus 1.98 1.19–3.29 0.01
Age 1.08 1.05–1.11 ,0.001
Male gender 3.02 1.72–5.28 ,0.001
Hypertension 2.32 1.18–4.54 0.01
Diabetes 1.82 1.04–3.18 0.04
Model 3
Phosphorus 1.92 1.56–3.19 0.01
Age 1.08 1.05–1.12 ,0.001
Male gender 2.85 1.62–5.02 ,0.001
Hypertension 2.36 1.19–4.66 0.01
Diabetes 1.77 1.01–3.13 0.05
Log PTH 0.42 0.12–1.45 0.17
Log FGF23 0.55 0.23–1.31 0.18
doi:10.1371/journal.pone.0036883.t003
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The association between serum phosphorus and cardiovascular
risk was first demonstrated in the CKD population. It has also
been associated with mortality [1,2] and vascular calcification in
CKD [24]. Subsequent studies [3,4] showed, for the first time, that
high-normal serum phosphorus levels are also associated with
mortality and cardiovascular events in the general population and
there is increasing evidence that phosphorus is associated with
atherosclerosis and CAD. It has been shown that phosphorus is an
independent predictor of carotid intima-media thickness in the
general population [7]. In an earlier study, Narang et al.
demonstrated a link between phosphorus and coronary artery
obstruction in the absence of renal dysfunction [5]. The authors
studied more than 300 patients and found that each 0.5-mmol/L
increase in serum phosphorus resulted in a 3 times greater chance
of having significant coronary disease [5]. Two longitudinal studies
recently found serum phosphorus to be a marker of incident and
progressive CAC in low-risk patients [25,26]. Our findings
confirm the predictive value of serum phosphorus in high-risk
patients. Likewise, we found that for each 0.1-mg/dl increase in
serum phosphorus the odds of having an abnormally high FS
increased by 7.4%.
In vitro studies have shown that hyperphosphatemia induces a
phenotypic transformation of vascular smooth muscle cells into
osteoblast-like cells that express biochemical markers characteristic
of the bone lineage, such as Runx2 [27], leading to calcification
[27]. In addition, high dietary phosphorus intake has been shown
to cause endothelial dysfunction in young men [28], and it has
been demonstrated that a phosphorus-enriched medium induces
bovine aortic endothelial cells to produce greater quantities of
reactive oxygen species and less nitric oxide [28]. Endothelial
dysfunction and vascular calcification are both involved in the
atherosclerotic process, and obstructive atherosclerotic lesions are
closely linked to vascular wall calcifications [29]. Vascular
calcification increases the risk of cardiovascular events, and an
AS.10 significantly increases mortality from cardiovascular
disease [23].
In CKD patients, FGF23 is associated with CAC [30], coronary
obstruction [17], and mortality [15]. A recent post hoc analysis of
the Heart and Soul study found FGF23 to be a predictor of
Table 4. Characteristics of the patients evaluated, by Friesinger scorea.
Characteristic Friesinger score Friesinger score p
#4 .4
(n=149) (n =137)
Age (years), mean 6 SD 55.869.2 60.368.9 ,0.001
Male gender, % 76 (51.0) 89 (64.9) 0.02
Hypertension, % 111 (74.5) 122 (89.05) 0.002
Diabetes, % 43 (38.8) 59 (43.0) 0.01
Current smoking, % 46 (30.8) 45 (32.8) 0.72
Statin use, % 59 (39.6) 89 (64.9) ,0.001
Alkaline phosphatase (U/L), mean 6 SD 75.3623.6 79.5624.6 0.06
Total calcium (mg/dl), mean 6 SD 9.460.5 9.560.5 0.80
Ionized calcium (mg/dl), median (IQR) 5.1 (4.9–5.3) 5.1 (5.0–5.3) 0.27
Phosphorus (mg/dl), mean 6 SD 3.560.6 3.660.5 0.04
25(OH)D (ng/ml), mean 6 SD 23.868.6 24.268.4 0.42
PTH (pg/ml), median (IQR) 60 (43–79) 52 (36–79) 0.18
FGF23 (pg/ml), median (IQR) 45.7 (31.7–76.1) 40.3 (24.1–62.2) 0.01
Creatinine (mg/dl), mean 6 SD 0.8760.16 0.9060.18 0.14
Urea (mg/dl), median (IQR) 36 (29–44) 37 (30–44) 0.63
Glucose (mg/dl), median (IQR) 104 (92–121) 105 (95–122) 0.33
Apolipoprotein B (mg/dl), mean 6 SD 89626 84623 0.35
Total cholesterol (mg/dl), mean 6 SD 177643 165640 0.03
HDL cholesterol (mg/dl), median (IQR) 45 (36–54) 42 (35–50) 0.05
LDL cholesterol (mg/dl), mean 6 SD 101636 93632 0.08
VLDL cholesterol (mg/dl), median (IQR) 25 (18–39) 26 (20–36) 0.52
Triglycerides (mg/dl), median (IQR) 129 (92–196) 131 (101–185) 0.56
C-reactive protein (mg/L), median (IQR) 2.5 (1.3–4.5) 3.2 (1.2–6.2) 0.14
C-peptide (ng/ml), median (IQR) 2.7 (1.9–3.6) 2.6 (1.8–3.7) 0.86
eGFR (ml/min/1.73 m2), median (IQR) 93.7 (79.7–106.7) 92.3 (79.4–11.2) 0.89
Agatston score 0 (0–35) 214 (87–838) ,0.001
25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; HDL, High-density lipoprotein; LDL, Low-density lipoprotein, VLDL, very low-density lipoprotein, eGFR,
estimated GFR.
aNormally distributed variables are expressed as mean 6 SD and non-normally distributed variables are expressed as median (IQR).
doi:10.1371/journal.pone.0036883.t004
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mortality [19] in the general population. In addition, analyses
derived from the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) study also demonstrated a positive
relationship between FGF23 and total body atherosclerosis in a
sample of 70-year-old patients [18]. These results are not in
accordance with our findings, which showed an inverse association
between FGF23 and coronary obstruction and no association
between FGF23 and CAC, a result in agreement with a previous
study [31]. One major explanation for that is that renal
dysfunction was not an exclusion criteria in the PIVUS and the
positive relationship between FGF23 and atherosclerosis might
result from that, particularly in older patients. Another possibility
is that the inverse association of FGF23, which persisted even after
adjustment for serum phosphorus itself, might reflect in patients
with normal kidney function the burden of phosphorus load and
the balance between FGF23 and all other mineral metabolism
elements.
In the absence of renal dysfunction, however, FGF23 deficiency
is characterized by hyperphosphatemia and ectopic calcifications
[32]. In contrast, excessive FGF23 production or activity results in
hypophosphatemia, osteomalacia [33], and rickets [34]. Never-
theless, there have been no reports of accelerated atherosclerotic
disease or increased cardiovascular events in individuals with
preserved renal function and high FGF23 levels, probably because
they are frequently hypophosphatemic. Another relevant differ-
ence between populations with and without renal dysfunction is
that the expression of klotho, a cofactor for FGF receptors
activation by FGF23 [35], is significantly impaired in the first
group. Therefore, the analysis of the associations of FGF23 with
coronary disease should be done separately from those patients
with CKD, even with a minor impairment, since the decrease of
Klotho expression is an early event in CKD [36].
This study has some limitations. First, the cross-sectional design
precludes the evaluation of causality and temporality among the
variables. Second, CAC and coronary obstruction are intermedi-
ary outcomes, and, despite being good markers of coronary events,
the associations found here cannot be extrapolated to clinical
outcomes such as mortality and cardiovascular events. Third,
calcitriol levels, phosphate excretion, and dietary intake were not
assessed, which could have improved the understanding of
phosphorus homeostasis in this population. Finally, the differences
in serum phosphorus between both the Agatston Score and
Friesinger Score groups were small (3.6 vs 3.5 mg/dl) and,
although they were statistically significant, this could mean a type
A error. Nevertheless, our patient sample was relatively large,
homogeneous and did not include patients with renal dysfunction.
We also excluded patients using medications or supplements that
might affect mineral and bone metabolism. Various mineral
metabolism markers were measured simultaneously, and CAD was
evaluated by quantifying CAC and obstruction in the same set of
patients. There have been no previous cross-sectional studies
demonstrating the value of phosphorus as a predictor of CAC.
Serum phosphorus is considered a nontraditional cardiovascular
risk factor in the CKD population and might confer risk in the
general population as well. We increasingly consume less natural
food and more processed food. Food processing typically
introduces high-phosphate additives and might be partially
responsible for phosphate intakes being well above the recom-
mended levels [37] and the deleterious effects of a high-phosphate
diet have yet to be fully understood. Considering the increasing
evidence of an association between phosphorus and cardiovascular
disease, it is important to prospectively investigate whether
interventions aimed at reducing the phosphate burden, such as
restricting dietary phosphorus and limiting the use of food
Table 5. Univariate and multivariate logistic regression of the
risk of having a Friesinger score higher than the median
(4 points).
Variable OR 95% CI p
Univariate analysis
Age 1.06 1.03–1.08 ,0.001
Male gender 1.78 1.11–2.87 0.02
White 1.96 1.19–3.22 0.01
Diabetes 1.86 1.14–3.04 0.01
Hypertension 2.78 1.45–5.34 0.002
Phosphorus 1.47 0.95–2.28 0.08
Agatston score (increase of 10) 1.06 1.03–1.07 ,0.001
Log PTH 0.47 0.16–1.35 0.16
Log FGF23 0.32 0.14–0.71 0.005
Multivariate models
Model 1
Phosphorus 1.59 1.02–2.48 0.04
Male gender 1.90 1.17–3.09 0.01
Model 2
Phosphorus 1.73 1.08–2.76 0.02
Male gender 2.43 1.44–4.09 0.001
Age 1.07 1.04–1.09 ,0.001
Model 3
Phosphorus 1.75 1.05–2.81 0.02
Male gender 2.63 1.54–4.47 ,0.001
Age 1.06 1.03–1.09 ,0.001
White 1.95 1.14–3.31 0.01
Model 4
Phosphorus 1.76 1.08–2.86 0.02
Male gender 2.61 1.51–4.51 ,0.001
Age 1.07 1.03–1.09 ,0.001
White 2.02 1.17–3.49 0.01
Log PTH 0.72 0.23–2.31 0.59
Log FGF23 0.28 0.12–0.67 0.003
Model 5
Phosphorus 1.73 1.06–2.82 0.03
Male gender 2.94 1.68–5.09 ,0.001
Age 1.06 1.03–1.09 ,0.001
White 1.99 1.16–3.41 0.01
Hypertension 2.71 1.34–5.49 0.01
Diabetes 1.46 0.85–2.49 0.16
Model 6
Phosphorus 1.74 1.06–2.88 0.03
Male gender 2.97 1.69–5.23 ,0.001
Age 1.06 1.03–1.09 ,0.001
White 2.07 1.19–3.61 0.01
Hypertension 2.79 1.36–5.70 0.01
Diabetes 1.51 0.87–2.61 0.15
Log PTH 0.77 0.23–2.54 0.67
Log FGF23 0.26 0.11–0.63 0.002
doi:10.1371/journal.pone.0036883.t005
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additives, reduce cardiovascular events and mortality in high-risk
patients or in the general population. The relationship between
FGF23 and cardiovascular disease in the absence of CKD also
merits further investigation.
In conclusion, we found that, in a clinically stable population
with suspected CAD and preserved renal function, serum
phosphorus was strongly and consistently associated with CAC
and coronary obstruction, as well as that FGF23 was negatively
associated with coronary obstruction.
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